Status:
COMPLETED
Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer
Lead Sponsor:
Qu Biologics Inc.
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive or invasive ade...
Detailed Description
Please refer to summary above.
Eligibility Criteria
Inclusion
- Male or female who is at or above the age of consent
- Histologically confirmed original diagnosis of lung cancer
- Life expectancy greater than 12 months
- ECOG performance status 0, 1, or 2 at screening
- Female subjects who agree to practice two effective methods of contraception from the time of signing the informed consent form through one month after the last dose of study drug
- Male subjects who agree to practice effective barrier contraception during the entire study drug period and through one month after the last dose of study drug
Exclusion
- Extra-thoracic lung cancer progression
- Any active malignancies
- Any uncontrolled or major organ dysfunction
- Any past or current radiation or systemic therapies for the treatment of lung cancer
- Known HIV infection or other immunosuppressive disorder
- Concurrently participating in another study with an investigational immunotherapy or have received investigational immunotherapy within 3 months prior to screening
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT02256852
Start Date
December 1 2014
End Date
November 1 2015
Last Update
February 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Cancer Research Centre
Vancouver, Canada